AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
NEW YORK, Dec. 07, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Cempra, Inc. (NASDAQ:CEMP) between October 22, 2015 and November 1, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Middle District of North Carolina. To get more information go to:
http://www.zlk.com/pslra/cempra-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, Cempra made false and/or misleading statements and/or failed to disclose that: (i) Cempra’s lead product candidate solithromycin posed significant safety risks for hepatotoxicity; and (ii) as a result of the foregoing, Cempra’s public statements were materially false and misleading at all relevant times.
On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review of solithromycin, highlighting a significant safety signal for hepatotoxicity. Upon this news, shares of Cempra fell over 60% during intraday trading.
If you suffered a loss in Cempra you have until January 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
